Ronac Mamtani is an Oncology physician affiliated with Hospital of the University of Pennsylvania. OpenAlex indexes 347 publications with 11,264 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd
2 West
Philadelphia, PA 191045127
Telephone
215-615-5858Registry record last updated 19 Sept 2019.
Clinical trials
- Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
Sponsor: Abramson Cancer Center at Penn Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments$19,680openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20251 payment
- Eli Lilly and CompanyProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Serotonin-3 Receptor Antagonist100%Ondansetron Odt100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2015–2019 per NIH RePORTER. The latest:
- Insulin resistance in the development and progression of invasive bladder cancer
University of Pennsylvania
FY2019$174,390K23CA187185 - Insulin resistance in the development and progression of invasive bladder cancer
University of Pennsylvania
FY2018$174,390K23CA187185 - Insulin resistance in the development and progression of invasive bladder cancer
University of Pennsylvania
FY2017$174,390K23CA187185
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Gad, MD, MPH
Hospital of the University of Pennsylvania
Lawrence Wechsler, MD
Hospital of the University of Pennsylvania
John Hirshfeld, MD
Hospital of the University of Pennsylvania
Noelle Frey, MD
Hospital of the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”